TruBridge, Inc. (TBRG)
(Delayed Data from NSDQ)
$10.11 USD
-0.18 (-1.75%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $10.10 -0.01 (-0.10%) 7:58 PM ET
5-Strong Sell of 5 5
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TBRG 10.11 -0.18(-1.75%)
Will TBRG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TBRG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBRG
TruBridge (TBRG) Q1 Earnings Miss Estimates
TBRG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TBRG
TruBridge Announces Participation in the Stifel Cross Sector Insight Conference
TruBridge Awarded Peer Review Designation by Healthcare Financial Management Association
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)
TruBridge Inc (TBRG) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and ...